ClinicalTrials.gg
RecruitingNCT07462065Updated Mar 10, 2026

Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate

A Phase 4 interventional study of Clomiphene Citrate. and Pioglitazone (PIO) + Clomiphene citrate in Infertility Treatment and Pregnancy Rates, sponsored by PAEC General Hospital, Islamabad. Recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 38 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by PAEC General Hospital, Islamabad · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 38 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies testing clomiphene in Infertility — 1 open to participants now, 4 under way, 1 of them phase 3. Clomiphene · Infertility.

Planned enrollment
22nd of 33
62 · median 154
Started
2026
the only one that year
Phase 4
19 of 33
1 open now
Registered
32nd of 33
by date

Among the 33 studies testing clomiphene in Infertility, this one is the 22nd largest by planned enrollment, is the only one that started in 2026, is one of 19 in phase 4, and was the 32nd registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 33 studies testing clomiphene in Infertility is open now, in 1 country.

By country, each count listing its studies:

About clomiphene

Clomiphene: first FDA approval 1967 (CLOMID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 38 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing clomiphene in Infertility, or all of them as a file.
02

Study summary

Women who meet the study requirements will be enrolled and randomly assigned by a computer system to receive either pioglitazone 30 mg daily or a placebo starting from the second day of their menstrual period for the same duration. All participants will also take clomiphene citrate 150 mg daily from day 3 to day 7 of the menstrual cycle. A transvaginal ultrasound will be performed on day 10 of the menstrual cycle to assess the growth of ovarian follicles, and the number of mature follicles (16-24 mm) will be recorded. If at least one mature follicle measuring 16-24 mm is present and the endometrial thickness is at least 7 mm, an injection of human chorionic gonadotropin (hCG) will be given to trigger ovulation, followed by an intrauterine insemination (IUI) procedure. Participants will be followed until the end of the menstrual cycle, and if the menstrual period is delayed by 5 days, a blood test for β-hCG will be performed to confirm pregnancy. Any side effects during the treatment period, such as swelling, fluid retention, blurred vision, or weight gain, will be recorded.

Read the detailed description

Patients fulfilling the inclusion criteria will be enrolled and randomized using computer-generated random numbers to receive either pioglitazone 30 mg daily or a placebo starting from the second day of menstruation for a similar duration. All participants will receive clomiphene citrate 150 mg between the third and seventh days of the menstrual cycle. Transvaginal sonography will be performed on the 10th day of the menstrual cycle, and the number of large follicles (16-24 mm) will be recorded. Human chorionic gonadotropin (hCG) will be administered to patients with at least one follicle measuring 16-24 mm and an endometrial thickness of at least 7 mm, followed by intrauterine insemination (IUI). Patients will be followed until the end of the menstrual cycle, and in cases of a 5-day delay in menstruation, a blood sample will be obtained to measure β-hCG for biochemical confirmation of pregnancy. Any adverse effects observed during the treatment period, including edema, fluid retention, blurred vision, or weight gain, will be documented.

03

Conditions studied

  • Infertility Treatment
  • Pregnancy Rates

Browse trials for

Keywords

  • Clomiphene citrate
  • Pioglitazone
04

Who can participate

Ages eligible
18 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Normal hysterosalpingography Normal spermogram Suffering from PCOS Ovarian cysts less than 20mm.

Exclusion criteria

Exclusion Criteria:

History of chronic cardiovascular disease Chronic kidney disease Diabetes Thyroid disease Pulmonary disease

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Group C

    Drug: Clomiphene Citrate.

  • Active comparator
    Group CP

    Drug: Pioglitazone (PIO) + Clomiphene citrate

Interventions

  • DrugClomiphene Citrate.

    150 mg clomiphene citrate will be administered at third and seventh days of the menstrual cycle

  • DrugPioglitazone (PIO) + Clomiphene citrate

    Drug pages: PioglitazoneStudies of PioglitazonePioglitazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClomipheneStudies of ClomipheneClomiphene pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 30 mg pioglitazone daily; from the second day of menstruation along with 150 mg clomiphene citrate will be administered to both groups between the third and seventh days of the menstrual cycle.

06

What researchers measure

Primary outcomes

  1. Ovarian stimulation rate

    This will be determined by no. of large size follicles (16-24mm in size) recruited following treatment on 10th day of menstrual cycle using transvaginal ultrasound to measure the size and no. of follicles.

    Time frame: 10th day of menstrual cycle

Secondary outcomes

  1. Pregnancy rates

    It will be measured in terms of number of patients out of total number treated who conceived. This will be confirmed clinically as well as by measuring serum bHCG levels if patient doesn't not menstruate for more than 5 days following end of her reproductive cycle.

    Time frame: 5th day after end of menstrual cycle

07

Study locations

1 of 1 sites recruiting
  • Pakistan Atomic Energy Commission Hospital
    Islamabad, Federal 44000, Pakistan
    Recruiting
08

References and documents

Publications

  • Amirian M, Shariat Moghani S, Jafarian F, Mirteimouri M, Nikdoust S, Niroumand S, Salehi M, Payrovnaziri A. Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome. BMC Womens Health. 2021 Aug 17;21(1):302. doi: 10.1186/s12905-021-01448-5. PubMed 34404415 ↗

Individual participant data

Plan to share: No — Ethical committee doesnt allow data sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2026, 3 months after the start.

Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 3 months is below that.

Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462065
Lead sponsor
PAEC General Hospital, Islamabad
Responsible party
Kinza Azhar (Principal Investigataor, PAEC General Hospital, Islamabad) — Principal investigator
First posted
Mar 10, 2026
Start date
Mar 1, 2026
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Kinza Principal Investigator, MBBS
Contact
kinza.azharr@gmail.com
+92-333-3275552
Musarat Ashraf, MBBS,FCPS
study chair · Head of Department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Clomiphene

Start the discussion